Jane Street
PPBT

Jane Street’s Purple Biotech PPBT Stock Holding History

Jane Street’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10
Closed -$24K – 7756
2020
Q2 		$24K Buy
+10
New +$9.83K ﹤0.01% 6950
2016
Q4 		– Sell
-7
Closed -$49K – 4482
2016
Q3 		$49K Buy
7
+1
+17% +$6.24K ﹤0.01% 3895
2016
Q2 		$35K Buy
+6
New +$60.1K ﹤0.01% 3972

Other funds holding PPBT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Bedel Financial Consulting Indianapolis, Indiana $888M AUM 19.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jane Street's PPBT Position: Q3 2020 in Review

Jane Street sold out of Purple Biotech (PPBT) in Q3 2020, closing a stake of 10 shares — an estimated $24K sold.

Jane Street first reported a position in PPBT in Q2 2016 and held it in 3 quarters. The position peaked at $49K in Q3 2016. 15 funds tracked by Wall St. Rank hold PPBT as of Q3 2020.

  • Jane Street reported no remaining Purple Biotech position as of Q3 2020 after selling out during the quarter.
  • Jane Street sold 10 Purple Biotech shares in Q3 2020, an estimated $24K.
  • Jane Street first reported a position in Purple Biotech in Q2 2016 and held it in 3 quarters.
  • Jane Street's Purple Biotech position peaked at $49K in Q3 2016.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2020.

Based on Jane Street's 13F filing for Q3 2020, filed 17 Nov 2020.